Genus Oncology Overview
- Year Founded
-
2007
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
2ndary - Private
- Investors
-
2
Genus Oncology General Information
Description
Developer of peptide-and antibody-based drugs designed to treat cancer. The company's focus is in discovering and developing first-in-class agents against the MUC1-C oncoprotein for the treatment of patients with refractory cancers and developing novel therapeutics, enabling healthcare providers to improve the lives of the cancer patients.
Contact Information
Website
www.genusoncology.comCorporate Office
- 650 Albany Street
- Boston, MA 02118
- United States
Corporate Office
- 650 Albany Street
- Boston, MA 02118
- United States
Genus Oncology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 2. Early Stage VC (Series A) | 01-May-2011 | Completed | Generating Revenue | |||
| 1. Grant | 01-Jan-2008 | $100K | Completed | Generating Revenue |
Genus Oncology Patents
Genus Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2015211034-B2 | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) | Active | 29-Jan-2014 | ||
| AU-2015211034-A1 | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) | Active | 29-Jan-2014 | ||
| JP-2021100942-A | Antibodies against muc1-c/extracellular domain (muc1-c/ecd) | Active | 29-Jan-2014 | ||
| ES-2794088-T3 | Antibodies against the extracellular domain of muc1-c (muc1-c / ecd) | Active | 29-Jan-2014 | ||
| EP-3099719-B1 | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) | Active | 29-Jan-2014 | C07K16/3092 |
Genus Oncology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Genus Oncology Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Cancer Institute | Government | |||
| U.S. Department of Health and Human Services | Government |
Genus Oncology FAQs
-
When was Genus Oncology founded?
Genus Oncology was founded in 2007.
-
Where is Genus Oncology headquartered?
Genus Oncology is headquartered in Boston, MA.
-
What is the size of Genus Oncology?
Genus Oncology has 6 total employees.
-
What industry is Genus Oncology in?
Genus Oncology’s primary industry is Drug Discovery.
-
Is Genus Oncology a private or public company?
Genus Oncology is a Private company.
-
What is Genus Oncology’s current revenue?
The current revenue for Genus Oncology is .
-
How much funding has Genus Oncology raised over time?
Genus Oncology has raised $25M.
-
Who are Genus Oncology’s investors?
National Cancer Institute and U.S. Department of Health and Human Services have invested in Genus Oncology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
